Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.



Lee Pratley's Articles

Neuro-Bio Attracts Over $3 Million In Series A Investment To Develop A New Approach To Alzheimer’s Disease

Oxford, UK Neuro-Bio Ltd, a UK-based early stage biopharmaceutical company focussingon neurodegenerative diseases, today announced it has received Series A funding of $3.2 million from US-based Kairos Ventures to continue developing a diagnostic tool for early detection of Alzheimer’s and to discover new drugs targeting the disease. Neuro-Bio has been pioneering a novel approach to Alzheimer’s disease and related neurodegenerative disorders since 2013. The innovative Neuro-Bio technology is the result of over 40 years of basic research by Baroness Professor Susan Greenfield's group, initially at Oxford University, that points to a previously unidentified mechanism underlying the continuing cycle of cell death that characterises the neurodegenerative process. The company has been exploring whether activation of this brain mechanism could be halted by pharmaceutical intervention and how these changes are reflected in a biomarker present in blood. The new investment will allow Neuro-Bio to develop the biomarker into a diagnostic tool and to make substantive progress towards identifying a lead compound with promising therapeutic potential in Alzheimer’s disease.

Elasmogen Receives £1.2m In Grant And Equity Investment

Elasmogen Ltd, developer of soloMERTM biologics, today announced that it has received a Biomedical Catalyst Grant from the UK’s innovation agency, Innovate UK and matching investment from Deepbridge Capital and Scottish Investment Bank (the investment arm of Scottish Enterprise) totalling £1.2 M. The funding will be used to develop ELN-21 and ELN-22, the companies’ next generation biologics for topical treatment of ocular disease.

Oxford Immunotec Announces Release of New National Tuberculosis Test Data and Screening Grant for High Risk Patients on World TB Day

OXFORD, United Kingdom and MARLBOROUGH, Mass., March 23, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq: OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced the release of national T-SPOT®.TB test positivity rates within the United States and United Kingdom, as well as a grant to support TB screening for high risk patients.

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.

OBN Noticeboard

This is an impromptu noticeboard to let people know about events, other things that are happening, perhaps lab equipment for sale etc.  Just drop an email to us, team@obn.org.uk, and we will post.

Don't forget about the 'wandering kitchens' near No. 99 on Milton Park on Thursday lunchtime!